Cartesian Therapeutics, Inc. (NasdaqGM: RNAC)
Health Care · Biotechnology · US
$7.06
-4.14% today · -25.7% 1Y
Cartesian Therapeutics, Inc. (NasdaqGM: RNAC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $213.45M and employs 75 people.
Over the last twelve months the share price has lost 25.7%, trading between 5.60 and 11.00.
Tweenvest scores Cartesian Therapeutics, Inc. across four factors: quality 33/100, value 38/100. Its strongest factor is value.
RNAC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $213.45M
- Revenue (TTM)
- $1.48M
- P/E
- —
- EPS
- -5.61
- Dividend yield
- —
- Beta (5Y)
- 0.72
- 52-week high
- $11.00
- 52-week low
- $5.60
- Avg volume (3M)
- —
- Shares outstanding
- 30.26M
- Employees
- 75
- Next earnings
- —
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
- ISIN
- US8162123025
- Listed since
- Jun 22, 2016
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| HansBiomed CorporationKOSDAQ: A042520 | $219.06M | ₩20,650.00 | -2.82% |
| Panacea Biotec LimitedNSEI: PANACEABIO | $218.50M | Rs345.25 | -3.84% |
| Transgene SAENXTPA: TNG | $214.67M | €0.70 | +2.19% |
| Beijing Biostar Pharmaceuticals Co., Ltd.SEHK: 2563 | $213.47M | HK$4.30 | -10.97% |
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $213.44M | $8.71 | -5.94% |
| Genome & CompanyKOSDAQ: A314130 | $212.80M | ₩5,470.00 | -0.55% |
| Invivyd, Inc.NasdaqGM: IVVD | $212.58M | $0.72 | -12.27% |
| Guangzhou Innogen Pharmaceutical Group Co., LtdSEHK: 2591 | $209.56M | HK$3.60 | -3.49% |
Figures last refreshed Oct 11, 2026.